A5060093054- Inflammatory Bowel Disease
- Microscopic Colitis
- Gastrointestinal motility and disorders
- Clostridium difficile and Clostridium perfringens research
- Clusterin in disease pathology
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Helicobacter pylori-related gastroenterology studies
- Immunodeficiency and Autoimmune Disorders
- Gut microbiota and health
- Eosinophilic Esophagitis
- Pregnancy and Medication Impact
- Chemotherapy-induced organ toxicity mitigation
- Gastric Cancer Management and Outcomes
- Biomarkers in Disease Mechanisms
- Liver Diseases and Immunity
- IL-33, ST2, and ILC Pathways
- Inflammasome and immune disorders
- Genetic factors in colorectal cancer
- Tryptophan and brain disorders
- Pharmacological Effects and Toxicity Studies
- Autoimmune and Inflammatory Disorders Research
- Potassium and Related Disorders
- Pharmacological Effects of Natural Compounds
- Renal Transplantation Outcomes and Treatments
Osaka University of Pharmaceutical Sciences
2022-2025
Fluoropyrimidines (FPs) are key drugs in many chemotherapy regimens; however, recipients often prone to diarrhea due gastrointestinal toxicity. Disruption of the intestinal epithelial barrier function by FPs leads dysbiosis, which may exacerbate cell damage as a secondary effect and trigger diarrhea. However, despite studies on chemotherapy-induced changes microbiome humans, relationship between dysbiosis is unclear. In this study, we aimed investigate microbiome.We conducted single-center...
Background: In recent years, various biomarkers of ulcerative colitis (UC) have emerged; however, few studies simultaneously examined the utility multiple for monitoring disease activity. Additionally, serum leucine-rich alpha-2 glycoprotein (LRG), a new biomarker, may show blunt response to anti-TNF antibody therapy. This prospective study explored effective that could monitor activity changes in patients with UC. addition, we effect therapy on LRG. Methods: Blood and stool samples were...
The calcineurin inhibitor tacrolimus is reportedly effective for moderate/severe ulcerative colitis (UC); however, it also associated with nephrotoxicity. We investigated the risk factors tacrolimus-induced nephrotoxicity and whether renal impairment adversely affected outcomes of treatment in patients UC.We conducted a retrospective study 93 UC who were administered leading to high trough levels (10-15 ng/mL) 2 weeks low (5-10 3 months.Acute kidney injury (AKI) occurred 44 (47.3%) during...
Abstract Background Endoscopic mucosal healing serves as a critical predictor for achieving long-term remission in Crohn’s disease treatment. Recent data indicate that the effectiveness of varies based on location gastrointestinal inflammation. Additionally, reports suggest antitumor necrosis factor-α (anti-TNF-α) agents exhibit reduced efficacy treating small intestinal inflammation compared to colorectal Conversely, limited research exists regarding impact anti-IL12/23 agent ustekinumab...
Tacrolimus (TAC) effectively induces remission in refractory ulcerative colitis (UC). However, TAC therapy usually lasts for 3 months. Although azathioprine (AZA) is often used maintenance therapy, the relapse rate remains high. Herein, we evaluated efficacy of adalimumab (ADA) patients with UC after induction TAC. We prospectively enrolled moderate-to-severe who achieved clinical months endoscopic non-mucosal healing (Cohort A). After discontinuation, up to 1 year starting ADA was examined....
Background: Tacrolimus (TAC) effectively induces remission in refractory ulcerative colitis (UC). However, TAC therapy usually lasts for 3 months. Although azathioprine (AZA) is often used maintenance therapy, the relapse rate remains high. Herein, we evaluated efficacy of adalimumab (ADA) patients with UC after induction TAC.
 Methods: We prospectively enrolled moderate-to-severe who achieved clinical months endoscopic non-mucosal healing (Cohort A). After discontinuation, up to 1 year...
Ustekinumab, a new anti-interleukin-12/23 antibody, is an effective treatment for ulcerative colitis; however, data regarding predictive factors of its efficacy are limited. Predicting in advance would be useful selecting therapeutic agent. This study aimed to identify biomarkers that can predict the long-term outcome ustekinumab treatment.
A certain number of patients with ulcerative colitis (UC) are refractory to anti-TNF-α antibodies; biomarkers thus needed predict treatment efficacy. This study aimed evaluate whether serum that were reported be associated UC or antibody could the response golimumab, a human monoclonal antibody, in bio-naïve UC. We prospectively enrolled 23 consecutive who treated golimumab. Serum samples collected before first golimumab dose. Eleven molecules measured by electrochemiluminescence (ECL)...
A considerable number of patients with ulcerative colitis (UC) who initially respond to golimumab (GLM), an anti-TNF-α antibody, gradually lose clinical response. Therapeutic drug monitoring has been proposed optimize serum antibody concentrations before the loss response; however, little is known about ideal GLM concentrations. We aimed evaluate whether trough levels (TLs) early after initiation induction therapy affect long-term outcomes in UC and identify TLs that should be targeted for...
Ustekinumab, a new anti-interleukin-12/23 antibody, is an effective treatment for ulcerative colitis; however, data regarding predictive factors of its efficacy are limited. This study aimed to identify biomarkers that can predict the long-term outcome ustekinumab treatment. We retrospectively reviewed records patients with active colitis treated at our hospital from June 2020 January 2023. divided into non-remission and remission groups, examined whether baseline biomarkers, including...